Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire‐Lung Cancer 13 (QLQ‐LC13) covers 13 typical symptoms of lung cancer …

Introduction The main objective of the current post hoc analysis was to compare patient-
reported outcomes between crizotinib (N= 172) and chemotherapy subgroups (pemetrexed …

Patient-reported outcomes (PROs) are increasingly used to monitor treatment-related
symptoms and physical function decrements in cancer clinical trials. As more patients enter …

The search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has
witnessed a swift evolution. The number of targeted drugs that can improve patient …

The availability of targeted drugs has made the assessment of the EGFR mutation and ALK
rearrangement critical in choosing the optimal treatment for patients with advanced non …

Introduction Given the relatively short life expectancy of patients with hepatocellular
carcinoma (HCC), quality of life (QOL) plays a significant role in treatment selection. This …

Background: The majority of lung cancer patients are diagnosed with advanced non-small
cell lung cancer (NSCLC), the bulk of which receive palliative systemic treatment with the …

Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for
patients with EGFR mutation-positive (EGFR m+) advanced non-small-cell lung cancer …